SCOPUS 정보 검색 플랫폼

Journal of Heterocyclic Chemistry

Volumn 45, Issue 2, 2008, Pages 611-614

Microwave-assisted Döbner synthesis of 2-phenylquinoline-4-carboxylic acids and their antiparasitic activities

(4) Muscia, Gisela C a Carnevale, Juan P a Bollini, Mariela a Asís, Silvia E a

a UNIVERSIDAD DE BUENOS AIRES (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 HYDROXYPHENYL)QUINOLINE 4 CARBOXYLIC ACID; 2 (2 NITROPHENYL)QUINOLINE 4 CARBOXYLIC ACID; 2 (4 CHLOROPHENYL)QUINOLINE 4 CARBOXYLIC ACID; 2 (4 HYDROXYPHENYL)QUINOLINE 4 CARBOXYLIC ACID; 2 (4 METHOXYPHENYL)QUINOLINE 4 CARBOXYLIC ACID; 2 PHENYL 7 TRIFLUOROMETHYLQUINOLINE 4 CARBOXYLIC ACID; 2 PHENYLQUINOLINE 4 CARBOXYLIC ACID; 6 CHLORO 2 PHENYLQUINOLINE 4 CARBOXYLIC ACID; 6 FLUORO 2 PHENYLQUINOLINE 4 CARBOXYLIC ACID; 7 CHLORO 2 PHENYLQUINOLINE 4 CARBOXYLIC ACID; 7 METHYL 2 PHENYLQUINOLINE 4 CARBOXYLIC ACID; 8 CHLORO 2 PHENYLQUINOLINE 4 CARBOXYLIC ACID; ARTEMETHER; BENZNIDAZOLE; CARBOXYLIC ACID DERIVATIVE; CHLOROQUINE; MELARSOPROL; MILTEFOSINE; NICLOSAMIDE; NIFURTIMOX; PODOPHYLLOTOXIN; STIBOGLUCONATE SODIUM; SURAMIN; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; LEISHMANIA INFANTUM; LEISHMANIASIS; MALARIA; MICROWAVE IRRADIATION; NONHUMAN; PLASMODIUM FALCIPARUM; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS;

EID: 40949162431 PISSN: 0022152X EISSN: None Source Type: Journal
DOI: 10.1002/jhet.5570450251 Document Type: Article

Times cited : (24)

References (19)

1
- 11844282171
- Kouznetsov, V. V.; Vargas Méndez, L. V.; Meléndez Gómez, C. M. Current Org. Chem. 2005, 9, 141.
- (2005) Current Org. Chem , vol.9 , pp. 141
- Kouznetsov, V.V.¹ Vargas Méndez, L.V.² Meléndez Gómez, C.M.³

2
- 14644443491
- Ncokazi, K. K.; Egan, T. J. Anal. Biochem. 2005, 338, 306.
- (2005) Anal. Biochem , vol.338 , pp. 306
- Ncokazi, K.K.¹ Egan, T.J.²

3
- 40949161768
- a) Richomme, P.; Bruneton, J.; Hocquemiller, R.; Roblot, F.; Cavé, A.; Fournet, A. J. Nat. Prod. 1993, 56, 1547.
- (1993) J. Nat. Prod , vol.56 , pp. 1547
- Richomme, P.¹ Bruneton, J.² Hocquemiller, R.³ Roblot, F.⁴ Cavé, A.⁵ Fournet, A.⁶

4
- 2942594271
- b) Franck, X.; Fournet, A.; Prina, E.; Mahieux, R.; Hocquemiller, R.; Figadère, B. Bioorg. Med. Chem. Lett. 2004, 14, 3635.
- (2004) Bioorg. Med. Chem. Lett , vol.14 , pp. 3635
- Franck, X.¹ Fournet, A.² Prina, E.³ Mahieux, R.⁴ Hocquemiller, R.⁵ Figadère, B.⁶

5
- 0029965604
- Fournet, A.; Ferreira, M. E.; Rojas de Arias, A.; Torres de Ortiz, S.; Fuentes, S.; Nakayama, H.; Schinini, A.; Hocquemiller, R. Antimicrob. Agents Chemother. 1996, 2447.
- (1996) Antimicrob. Agents Chemother , pp. 2447
- Fournet, A.¹ Ferreira, M.E.² Rojas de Arias, A.³ Torres de Ortiz, S.⁴ Fuentes, S.⁵ Nakayama, H.⁶ Schinini, A.⁷ Hocquemiller, R.⁸

6
- 33144458046
- Vega, M. C.; Montero Torres, A.; Marrero-Ponce, Y.; Rolón, M.; Gómez-Barrio, A.; Escario, J. A.; Aran, B. J.; Nogal, J. J.; Meneses-Marcel, A.; Torrens, F. Bioorg. Med. Chem. Lett. 2006, 16, 1898.
- (2006) Bioorg. Med. Chem. Lett , vol.16 , pp. 1898
- Vega, M.C.¹ Montero Torres, A.² Marrero-Ponce, Y.³ Rolón, M.⁴ Gómez-Barrio, A.⁵ Escario, J.A.⁶ Aran, B.J.⁷ Nogal, J.J.⁸ Meneses-Marcel, A.⁹ Torrens, F.¹⁰

7
- 0031562030
- Gopalsamy, A.; Pallai, P. V. Tetrahedron Lett. 1997, 38, 907.
- (1997) Tetrahedron Lett , vol.38 , pp. 907
- Gopalsamy, A.¹ Pallai, P.V.²

8
- 0000513112
- Lutz, R. E.; Bailey, P. S.; Clark, M. T.; Codington, J. F.; Deinet, A. J.; Freek, J. A.; Harnest, G. H.; Leake, N. H.; Martin, T. A.; Rowlett, R. J.; Salsbury, J. M.; Shearer, N. H.; Smith, J. D.; Wilson, J. W. J. Am. Chem. Soc. 1946, 68, 1813.
- (1946) J. Am. Chem. Soc , vol.68 , pp. 1813
- Lutz, R.E.¹ Bailey, P.S.² Clark, M.T.³ Codington, J.F.⁴ Deinet, A.J.⁵ Freek, J.A.⁶ Harnest, G.H.⁷ Leake, N.H.⁸ Martin, T.A.⁹ Rowlett, R.J.¹⁰ Salsbury, J.M.¹¹ Shearer, N.H.¹² Smith, J.D.¹³ Wilson, J.W.¹⁴

9
- 32244445946
- Sivaprasad, G.; Rajesh, R.; Perumal, P. T. Tetrahedron Lett. 2006, 47, 1783.
- (2006) Tetrahedron Lett , vol.47 , pp. 1783
- Sivaprasad, G.¹ Rajesh, R.² Perumal, P.T.³

10
- 0035813242
- Perreux, I.; Loupy, A. Tetrahedron 2001, 57, 9199.
- (2001) Tetrahedron , vol.57 , pp. 9199
- Perreux, I.¹ Loupy, A.²

11
- 33646056650
- Tu, S.; Zhu, X.; Zhang, J.; Xu, J.; Zhang, Y.; Wang, Q.; Jia, R.; Jiang, B.; Zhang, J.; Yao, C. Bioorg. Med. Chem. Lett. 2006, 16, 2925.
- (2006) Bioorg. Med. Chem. Lett , vol.16 , pp. 2925
- Tu, S.¹ Zhu, X.² Zhang, J.³ Xu, J.⁴ Zhang, Y.⁵ Wang, Q.⁶ Jia, R.⁷ Jiang, B.⁸ Zhang, J.⁹ Yao, C.¹⁰

12
- 84862293494
- Döbner, O. Ann. 1887, 242, 265.
- (1887) Ann , vol.242 , pp. 265
- Döbner, O.¹

13
- 85036914844
- Beil., XXII, 518.
- a) Beil., XXII, 518.

14
- 85036931594
- b) Ibid. 104,
- Döbner, O.¹

15
- 85036936366
- c) Ibid. 105,
- Döbner, O.¹

16
- 85036916972
- d) Ibid. 520.
- Döbner, O.¹

17
- 33750608059
- Muscia, G. C.; Bollini, M.; Carnevale, J. P.; Bruno, A. M.; Asís, S. E. Tetrahedron Lett. 2006, 47, 8811.
- (2006) Tetrahedron Lett , vol.47 , pp. 8811
- Muscia, G.C.¹ Bollini, M.² Carnevale, J.P.³ Bruno, A.M.⁴ Asís, S.E.⁵

18
- 85036934412
- The in vitro protocols and activity criteria can be found at WHO website (, For antimalarial activity K1 strain is used, if the IC50 is >5 μg/mL, the compound is classified as inactive. If the IC50 is 0.5-5 μg/mL, the compound is classified as moderately active. If the IC50 is <0.5 μg/mL, the compound is classified as active and is further evaluated using two strains, K1 and NF54. For Chagas disease, if the IC50 is >30 μg/mL, the compound is classified as inactive. If the IC50 is between 2 and 30 μg/mL, the compound is classified as moderately active. If the IC 50 is <2 μg/mL, the compound is classified as active and is further evaluated in an in vivo screen. Regarding cytotoxicity, if the IC50 is > 90 μg/mL, the compound is classified as not cytotoxic. If the IC50 is between 2 and 89 μg/mL, the compound is c
- 50 is < 2 μg/mL, the compound is classified as cytotoxic.

19
- 85036938918
- Antwerp University, LMPH, standard procedures used for the TDR in vitro screening. For antimalarial activity GHA strain is used and for antileishmanial activity MHOM/MA(BE)/67 strain is used. The compound is classified as inactive when the IC50 is higher than 16 μg/mL. When IC50 lies between 16 and 1 μg/mL, the compound is regarded as being moderately active. When the IC50 is lower than 1 μg/mL, the compound is classified as active and is evaluated in a secondary screening. For Chagas disease, Trypanosoma cruzi β galactosidase strain is used. The compound is classified as inactive when the IC50 is higher than 16 μg/mL. When IC50 lies between 16 and 1 μg/mL, the compound is regarded as being moderate active. When the IC50 is lower than 1 μg/mL, the compound is classified as highly active and is further evaluated in a secondary screening. For toxicity, the compound is classified as non-toxic w
- 50 is lower than 4 μg/mL, the compound is classified as highly toxic.

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.